Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.

Doris K Hansen Surbhi Sidana Lauren C Peres Christelle M Colin-LeitzingerLeyla ShuneAlexandria ShrewsburyRebecca M Gonzalez Douglas W Sborov Charlotte B Wagner Danai DimaHamza HashmiMehmet Hakan Kocoglu Shebli AtrashGary SimmonsNilesh KalariyaChristopher FerreriAimaz Afrough Ankit Kansagra Peter M Voorhees Rachid C Baz Jack KhouriMelissa AlsinaJoseph P McGuirk Frederick L LockeKrina K Patel

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

The safety and efficacy of ide-cel in patients with RRMM in the SOC setting were comparable with those in the phase II pivotal KarMMa trial despite most patients (75%) not meeting trial eligibility criteria.

Keyphrases

phase ii
multiple myeloma
clinical trial
open label
phase iii
newly diagnosed
end stage renal disease
study protocol
chronic kidney disease
ejection fraction
acute myeloid leukemia
placebo controlled
double blind
peritoneal dialysis
prognostic factors